Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases

Authors :: Vivek Subbiah
Alexander Y. Andreev-Drakhlin
Maria E. Cabanillas
Behrang Amini
Source :: JCO Precision Oncology
Publication Year :: 2020
Publisher :: American Society of Clinical Oncology, 2020.

Subjects :: Cancer Research
Text mining
Oncology
business.industry
Mutant
Cancer research
Medicine
Medullary thyroid cancer
Cns activity
Case Reports
business
medicine.disease

Tools